STOCK TITAN

Executive changes at Cingulate (Nasdaq: CINGW) include pay and severance

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cingulate Inc. reported updates to executive compensation and a senior departure. The board had previously appointed John A. Roberts as Executive Chairman and placed CEO Shane Schaffer on administrative leave effective August 14, 2025. On August 22, 2025, the board set Mr. Roberts’ compensation at a cash retainer of $10,000 per month during his term as Executive Chairman, in lieu of non-employee director pay, and reduced Dr. Schaffer’s salary to 75% of his current level for the duration of his leave while keeping him eligible for standard employee benefits.

The company also detailed a Separation Agreement with former employee Laurie Myers following the end of her employment on August 7, 2025. Subject to her not revoking a release of claims within seven days, Ms. Myers will receive separation pay of $436,720 in semi-monthly installments over 12 months, her unvested stock options will vest and remain exercisable for their full term, and she remains bound by confidentiality, noncompetition, nonsolicitation, and non-disparagement obligations.

Positive

  • None.

Negative

  • None.
false 0001862150 0001862150 2025-08-22 2025-08-22 0001862150 CING:CommonStockParValue0.0001PerShareMember 2025-08-22 2025-08-22 0001862150 CING:WarrantsExercisableForCommonStockMember 2025-08-22 2025-08-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

August 22, 2025

 

CINGULATE INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40874   86-3825535
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

1901 W. 47th Place

Kansas City, KS 66205

(Address of principal executive offices) (Zip Code)

 

(913) 942-2300

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share    CING  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Warrants, exercisable for common stock   CINGW  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously disclosed, on August 14, 2025, the board of directors (the “Board”) of Cingulate Inc. (the “Company”) appointed John. A Roberts to serve as Executive Chairman of the Board (“Executive Chairman”) effective immediately and placed Shane Schaffer, the Company’s Chief Executive Officer, on administrative leave. In connection with such actions, on August 22, 2025, the Board determined that, effective as of August 14, 2025, Mr. Roberts will be paid a cash retainer of $10,000 per month during his term as Executive Chairman in lieu of compensation as a non-employee director. Also effective as of August 14, 2025, Dr. Schaffer’s salary was reduced to 75% of his current salary during the term of his leave. He will remain eligible to participate in the Company’s employee benefit plans on the same terms as other employees.

 

As previously disclosed, Laurie Myers’ employment with the Company ended on August 7, 2025. In connection with Ms. Myers’ departure, Cingulate Therapeutics LLC (“CTx”), a wholly-owned subsidiary of the Company, and Ms. Myers executed a Separation Agreement and Release of All Claims on August 28, 2025 (the “Separation Agreement”). Pursuant to the Separation Agreement: (i) Ms. Myers is subject to confidentiality, noncompetition and nonsolicitation covenants pursuant to her employment agreement with CTx dated September 23, 2021; and (ii) subject to Ms. Myers not timely revoking her release of claims within seven days of her execution of the Separation Agreement, Ms. Myers (a) released claims against the Company and its affiliates, (b) will receive a separation pay of $436,720 payable in semi-monthly installments for twelve (12) months, (c) unvested stock options will vest and be exercisable for their full term, and (d) is subject to certain post-employment restrictive covenants, including non-disparagement obligations.

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CINGULATE INC.
     
Dated: August 28, 2025 By: /s/ Jennifer L. Callahan
  Name: Jennifer L. Callahan
  Title: Interim Chief Executive Officer & Chief Financial Officer

 

 

FAQ

What executive leadership changes did Cingulate Inc. (CINGW) reference in this filing?

The company noted that its board had previously appointed John A. Roberts as Executive Chairman and placed CEO Shane Schaffer on administrative leave, both effective August 14, 2025. This filing focuses on the related compensation adjustments rather than announcing the leadership changes themselves.

How is Cingulate Inc. compensating Executive Chairman John A. Roberts?

Effective as of August 14, 2025, John A. Roberts will receive a cash retainer of $10,000 per month during his term as Executive Chairman. This payment is in lieu of his prior compensation as a non-employee director.

What happens to Cingulate CEO Shane Schaffer’s pay while he is on administrative leave?

Effective August 14, 2025, Dr. Shane Schaffer’s salary was reduced to 75% of his current salary for the duration of his leave. He remains eligible to participate in the company’s employee benefit plans on the same terms as other employees.

What severance will Laurie Myers receive from Cingulate Therapeutics LLC?

Under the Separation Agreement executed on August 28, 2025, and subject to her not revoking her release of claims within seven days, Laurie Myers will receive $436,720 in separation pay. This amount will be paid in semi-monthly installments over 12 months.

How are Laurie Myers’ stock options treated under her Separation Agreement with Cingulate?

The Separation Agreement provides that Ms. Myers’ unvested stock options will vest and will be exercisable for their full term, giving her the ability to exercise those options as if they had fully vested during employment.

What ongoing restrictions apply to Laurie Myers after leaving Cingulate?

Laurie Myers remains bound by confidentiality, noncompetition, and nonsolicitation covenants from her prior employment agreement, and the Separation Agreement adds post-employment restrictive covenants, including non-disparagement obligations.

Cingulate

NASDAQ:CINGW

CINGW Rankings

CINGW Latest News

CINGW Latest SEC Filings

CINGW Stock Data

3.83M
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY